New Study Links Enzyme with Poor Mesothelioma Outcomes, According to Surviving Mesothelioma
Italian researchers say a molecule linked with ovarian cancer may also affect the aggressiveness of malignant pleural mesothelioma.
Raleigh, NC (PRWEB) August 04, 2014
Scientists studying a call surface protein called CD157 say it can impact multiple aspects of mesothelioma – from how fast it grows to how easily it spreads – and may even affect chemotherapy response. Surviving Mesothelioma has just posted an article on the new research. Click here to read it now.
Researchers at the University of Torino in Torino, Italy say CD157, which has been associated with ovarian cancer, can be used to predict how fast mesothelioma will progress and how well it will respond to treatment. The affects were particularly pronounced in the biphasic type of mesothelioma.
“High CD157 was a negative prognostic factor and an independent predictor of poor survival for patients with biphasic malignant pleural mesothelioma by multivariate survival analysis,” report co-authors Dr. Erika Ortolan of the University of Torino Laboratory of Immunogenetics and oncologist and Dr. Alice Giacomino.
The study found high CD157 expression in four out of nine mesothelioma cell lines and in 85 percent of mesothelioma surgical tissue samples.
“Patients with biphasic mesothelioma often face a worse prognosis than people with other types of mesothelioma. If CD157 can help clinicians decide which patients are the best candidates for certain treatments, it has the potential to improve their survival odds,” says Surviving Mesothelioma’s Managing Editor, Alex Strauss.
The new study was published in a recent issue of the journal Oncotarget. To read more about the findings, see Enzyme Makes Mesothelioma More Aggressive, Less Responsive to Treatment, available now on the Surviving Mesothelioma website.
Ortolan, E et al, “CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome”, July 8, 2014, Oncotarget, Epub ahead of print, http://www.ncbi.nlm.nih.gov/pubmed/25026285
For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/08/prweb12061587.htm